BRD2 and familial pancreatic carcinoma: The authors determined that PDAC-PDOs exhibit differential sensitivity to each drug and PDOs derived from pre-NAT (100%) and post-NAT (71%) were able to predict the clinically observed response against oxaliplatin in patients treated with FFX, which is consistent with previous reports in pancreatic cancer [44].